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ABSTRACT
MicroRNA-dependent regulation in the preceding step of prostate cancer
Yoon Jin Cha
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Nam Hoon Cho)
Background: Prostatic intraepithelial neoplasia (PIN), convincingly
acceptable precursor lesion of prostate cancer (PCa), is characterized by 
obvious cytologic atypia in luminal cells with preserved basal cells. 
However, molecular association between PIN and PCa has been vaguely 
clarified. We aimed to identify miRNAs and surrogate target mRNA 
specific to regulate development of PIN and PCa, and to identify clinical 
implication of PIN as precancerous lesion of PCa.
Materials and methods: Among the 388 radical prostatectomy patients, 
69.3% harbored PIN, and large PIN was observed in 56 patients. 
Clinicopathologic analysis was performed based on the PIN status. To 
anlaysis miRNAs and surrogate target mRNAs, PIN clusters were 
obtained by macrodisseciton or laser capture microdissection from 
formalin-fixed paraffin embedded tissue. Using miRNA microarray 
screening analysis for each PIN or PCa to compare with normal prostatic 
tissue, top-ranked miRNAs with relatively lower expression were 
selected. Immunohistochemistry for FGFRL1, BACH1, ephrin-A3, 
STAT3, and ZEB1was performed, and expression level of the proteins in 
PCa, PIN, and normal prostatic tissue was analyzed. 
Results: Patients harbored PIN showed significant less lymphovascular 
invasion, less lymph node metastasis, lower tumor volume, lower 
Gleason score, lower death rate, longer overall survival compared to 
patients without PIN. Significant downregulation of miR-155, miR-210, 
miR-153, and miR-200c was observed. Subsequent validation step using 
- 2 -
immunohistochemistry against the candidate gene products revealed 
significant high expression of STAT3, ephrin-A3 and ZEB1 in PCa 
compared to PIN and normal prostatic tissue. Significant stepwise 
increase in expression of STAT3 and ZEB1 was observed from normal 
prostatic tissue to PCa. 
Conclusion: More favorable clinicopathologic parameters and longer 
overall survival in patients with PIN imply disease progression from PIN 
to PCa. Furthermore, downregulation of cancer-related miRNAs -
miR-155, miR-210, miR-153, and miR-200c- in both PIN and PCa and 
stepwise increased expression of STAT3 and ZEB1 support that PIN is a 
preceding lesion of PCa and early carcinogenesis starts at the molecular 
level.
----------------------------------------------------------------------------------------
Key words : Prostatic intraepithelial neoplasia, Prostatic neoplasms, 
MicroRNAs, STAT3, ZEB1
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MicroRNA-dependent regulation in the preceding step of prostate cancer
Yoon Jin Cha
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Nam Hoon Cho)
I. INTRODUCTION
Prostate cancer (PCa) is 5th common carcinoma in Korean men,1 the 
most common in American men, and one of cancer related leading cause of 
death.2 Detection of PCa at early stage is important because of excellent patients 
prognosis at early stage compared to the progressed state. With aid of routine 
PSA (prostate-specific antigen) screening and subsequent needle biopsies, 
detection rate of early PCa is increasing. 
As precursor of PCa, prostatic intraepithelial neoplasia (PIN) is most 
accepted candidate as preinvasive malignant lesion. Several studies showed that 
detection rate of carcinoma was higher in subsequent rebiopsies in patients 
having PIN in initial needle biopsies than patients without PIN in initial 
biopsies.1,3
Histologically, PIN is characterized by atypical epithelial proliferation 
in preexisting duct with intact basal cells, having four common morphologic 
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patterns including tufting (87%), micropapillary (85%), cribriform (32%) and 
flat (28%) patterns.4 Additional to its cytologic atypia like PCa, PIN has 
predilection in peripheral zone which is vicinity of carcinoma.5
Genetically, PIN demonstrates loss of chromosome 8p, which is also 
found in carcinoma.6 TMPRSS2 gene alteration is observed in 62% of PCa, 
17% of PIN, and none of normal prostate.7 There have been many studies of 
genetic alteration in tumor progression and metastasis of PCa, studies of genetic 
relationship between PIN and PCa are relatively rare. 6-8 MicroRNAs (miRNAs) 
are small non-coding RNAs that regulate the expression of mRNAs at 
post-transcriptional level. According to the targeted mRNA, miRNAs can act 
either oncogenic or tumor suppressive. In PCa, miRNAs influencing androgen 
signaling and cancer cell invasion and migration have been thoroughly studied 
to develop the therapeutic targets or biomarkers for prognosis. 9 However, 
miRNA state of PIN and its correlation of miRNA state of PCa has not been 
studied. 
In present study, we investigated clinical implication of PIN as 
precursor of PCa. We also aimed to verify the expression level of miRNAs in 
PIN and matched PCa, compared to normal prostatic tissue, and to find the 
target mRNAs and expression of related proteins involving the early 
carcinogenesis of PCa. 
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II. MATERIALS AND METHODS
1. Patient selection and clinicopathologic evaluation
Four hundred and twenty five radical prostatectomies were performed 
due to prostate cancer between 2005 and 2008 in Severance Hospital. 
Thirty-seven patients who had neoadjuvant anti-androgen therapy were 
excluded. As result, 388 radical prostatectomies comprised the population of 
this study. From medical chart review, clinical parameters including age, PSA 
level, overall survival and follow up period were recorded. For pathologic 
evaluation, after radical prostatectomy, the whole prostate specimen was made 
into whole mount slides. The specimen was fixed in buffered formalin (10%) 
after macroscopic examination. The apex of prostate was obtained by conization, 
and vertically sectioned to examine the bladder neck invasion. The basal region 
was shaved to evaluate the surgical margin. The main body was serially 
sectioned vertically to the urethra into 5-mm-thick slice from the apex to the 
base. The whole sectioned pieces were pictured and fully embedded. Each 
paraffin block was cut into 4-μm-thick slices and stained with hematoxylin and 
eosin for a microscopic examination. Whole mount slides of prostates were 
reviewed by two pathologists (NHC and YJC) for Gleason score, pathologic T 
stage, lymph node metastasis, perineural invasion, lymphovascular invasion, 
tumor volume. Grid method 10 was used for measuring the tumor volume. Either 
the presence or absence of PIN was reviewed for each patient. PIN was 
categorized, in more detail, as follows; absence of PIN, presence of small PIN, 
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and presence of large PIN. Large PIN was defined well-defined lesions 
absolutely composed of high grade PINs at least more than 2 mm2 (one x100 
magnification field) (Fig 1A).
Figure 1. Grouped prostatic intraepithelial neoplasia (PIN) and comfirmation 
with immunohistochemistry. (A) Under low power magnification, grouped PIN 
is well delineated (hematoxylin and eosin, x12.5). (B) The lesion is composed 
of atypical luminal epithelial cells with intact basal cell layer (hematoxylin and 
eosin, x100). (C and D) P63 and high molecular weight cytokeratin (HMWCK) 
immunohistochemical stainings reveals intact basal cell layer of PIN, compared 
to the adjacent carcinoma. (C, p63, x100, D, HMWCK, x100)
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Figure 2. Laser capture microdissection for prostatic intraepithelial neoplasia.
Before (A) and after (B) of laser capsure microdissection of prostatic intraepithelial 
neoplasia in the area of interemixed PIN and prostate cancer
2. Tissue sampling of PIN by laser caputure microdissection and 
macrodissection from formalin-fixed, paraffin-embedded tissue
PIN is pathologically characteristic of atypical luminal cells sufficient
for prostate cancer but with preservation of basal cells (Fig. 1B). Multifocal 
isolated or clusters of PIN were confirmed by loss of basal cells using both p63 
nuclear stain and CK HMW membranous stain restricted to basal cells (Fig 1C 
and 1D). Immunohistochemically-proven PINs were removed by laser capture 
microdissection (Fig 2). 
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Microdissection of PIN was performed by Leica LMD7000 (Leica 
Microsystems, Wetzlar, Germany) from FFPE tissue. 5-μm-thick paraffin 
sections were stained with hematoxylin and eosin, mounted on crosslinked 
polyethylene (PEN) foil attached to a carrying frames. After defining PIN area, 
ultraviolet laser cut the edge around PIN on the foiled slides. The laser beam 
was moved by optics to ensure the precision. The microdissected tissue was 
transported by gravity without contact by pressure of laser beam. To test the 
efficiency of DNA isolation, 50–2000 cells were microdissected.
Macrodissection was also performed to obtain large grouped PIN, by 
using sharp 24-gauaged needle after dripping xylene directly on cover-glass 
removed slide. 
  
3. MicroRNA microarray and prediction of putative targets of miRNAs
Ten specimens including large grouped PIN were selected for miRNA
preparation. Paired PIN and PCa were obtained from FFPE tissue in each 
patient by laser capture microdissection and macrodissection. Benign prostatic 
tissue was obtained from transurethral resection of prostate of 2 patients having 
nodular hyperplasia for reference control. miRNA was separated from minimum 
400 ng of total RNA using the PANArray™ miRNA expression profiling kit 
following the company’s protocol. Fluorescein-labeled 135 cancer-related 
miRNA probes were used and signal intensities were measured as previously 
described.11 Raw data were normalized by intensity of RNU6B in each sample,
- 9 -
and analyzed in Genepix 4000B scanner and PANAGENE software. 
Compared with normal prostatic tissue, miRNAs showing more than 2, 
less than 0.5 fold of intensity signal in PIN and PCa were selected. For each 
miRNA, miRanda (http://www.microrna.org/microrna/home.do), TargetScan 
(http://www.targetscan.org/vert_61/), miRBase (http://www.mirbase.org) were 
used to predict putative targets. Additionally, prior studies about the each 
miRNA related cancer and/or prostate were reviewed. 
4. Immunohistochemical staining and interpretation 
Available immunohistochemical staining for FFPE tissue was
performed with antibodies against FGFRL1 (Abcam, ab95940, 1:100), BACH1 
(Novus, NBP2-01904, 1:300), Ephrin-A3 (Novus, NBP1-19540, 1:100), STAT3 
(Santacruz, sc-8019, 1:100), and ZEB1 (Cell signaling, D80D3, 1:100). Briefly, 
4-µm-thick paraffin sections were deparaffinized and rehydrated by xylene and 
alcohol solution. Immunohistochemistry was performed using the Ventana 
Discovery XT automated stainer (Ventana Medical System, Tucson, AZ, USA). 
Antigen retrieval was performed using CC1 buffer (Cell Conditioning 1; citrate 
buffer Ph 6.0, Ventana Medical System). Appropriate positive and negative 
controls for immunohistochemistry were included. Immunohistochemical 
staining of all cases were assessed by two pathologists (YJC and NHC), using 
light microscopes. Nuclear staining for BACH1, and cytoplasmic staining for 
FGFRL1, Ephirin-A3, and STAT3 were considered as positive. Interpretation of 
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immunohistochemical staining was determined by multiplying the proportion of 
stained cell (0% = 0, 1-5% = 1, 6-25% = 2, 26-50% = 3, 51-100% = 4) with the 
immunostaining intensity (negative = 0, weak = 1, moderate = 2, strong = 3).12
5. Statistics
Data were analyzed with SPSS for Windows (version 18.0; SPSS Inc., 
Chicago, IL, USA). For analysis of numerical variables in three subgroups of 
patients, one-way ANOVA test and Kruskal-Wallis test were performed. 
Chi-square test was used for comparison of categorical variables. Friedman test 
and Wilcoxon signed rank test were performed to analyze immunohistochemical 
staining score. Kaplan-Meier survival curves and log-rank statistics were 
employed to evaluate time to survival. P<0.05 was considered significant.
III. RESULTS
1. Clinicopathologic profile based on PIN status
Of total 388 patients, mean age was 63.45±7.53 years (range 38-84 
years), mean PSA level was 14.36±40.51 mg/dL (range 2.0-726.6 mg/dL), 
mean follow up period was 80.54±18.69 months (range 0.8-112.4 months). 
When 388 patients were separated into 3 groups according to the PIN status, 
119 (30.7%) had no PIN, 213 (54.9%) had small PIN, and 56 (14.4%) had large 
PIN over 2 mm2 in maximal dimension. Patients with PIN had significantly 
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lower serum PSA (p=0.003), lower Gleason score (p=0.007), lower invasive 
tumor volume (p=0.001), less lymphovascular invasion (p=0.046), less lymph 
node metastasis (p<0.001), and less death rate (p=0.03). No significant
difference was found in patient age, pathologic T stage, and perineural invasion. 
When patients with small PIN and large PIN were compared, there was no 
significantly different parameter. The clinicopathologic profile is summarized in 
Table 1. Overall survival was significantly shorter in patients without PIN 
(p<0.001). (Fig. 3)
Table 1. Clinicopathologic profiles of patients
Absence of 
PIN (n=81)
Presence of small 
PIN (n=191)
Presence of 
large PIN 
(n=41)
Age (mean, years)
64.44±7.30 62.89±7.80 63.46±6.85
Serum PSA (mean, 
mg/dL) *, †, ‡
25.06±71.58 10.06±8.90 8.40±5.118
Gleason score *, †, ‡
7.13±1.21 6.80±0.95 6.73±0.65
Volume of invasive 
carcioma (cc) *, †, ‡
4.50±7.06 2.49±3.90 2.18±1.76
Pathologic T stage
2
73 (61.3%) 146 (68.5%) 37 (66.1%)
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Absence of 
PIN (n=81)
Presence of small 
PIN (n=191)
Presence of 
large PIN 
(n=41)
3 45 (37.8%) 67 (31.5%) 19 (33.9%)
4 1 (0.8%) 0 (0.0%) 0 (0.0%)
Lymphovascular 
invasion *, †, ‡
16 (13.4%) 14 (6.6%) 2 (3.6%)
Perineural invasion
58 (48.7%) 88 (41.3%) 32 (57.1%)
Lymph node 
metastasis *, †, ‡
11 (9.2%) 2 (0.9%) 0 (0.0%)
Death *, †, ‡
15 (12.6%) 10 (4.7%) 3 (5.4%)
mean±standard deviation 
* p<0.05 among absence of PIN, presence of small PIN, and presence of large 
PIN
† p<0.05 between absence of PIN and presence of small PIN
‡ p<0.05 between absence of PIN and presence of large PIN
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Figure 3. Survival anaylsis of patients with and without prostatic intraepithelial
neoplasia (PIN) (green: patients with PIN; blue: patients without PIN)
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2. miRNA expression profile and in validation 
Twenty nine miRNAs showed detectable alteration in PIN/PCa or 
PIN/normal prostate among 135 cancer-related miRNA probes-platform array
(Fig. 4).
Figure 4. Normalization of miRNA array data (PIN, prostatic intraepithelial 
neoplasia; PCa, prostate cancer)
Following valid informatics programs, ultimately, four miRNAs were 
obtained when expression level of PIN was more than or less than 2-folds 
compared to normal control. MiR-155, miR-153, miR-200c, and miR-210 were 
significantly decreased in PIN and PCa. (Fig. 5)
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Figure 5. Surrogate candidates of miRNAs with normalized expression ratio between 
prostatic intraepithelial neoplasia and prostate cancer. 
3. mRNA screening specific to miRNA in silico   
Four mRNAs and their putative target genes were selected from 
miRanda (http://www.microrna.org/microrna/home.do), TargetScan 
(http://www.targetscan.org/vert_61/), miRBase (http://www.mirbase.org), and
previous published studies, which are tabulated in Table 2. 
- 16 -
Table 2. Selected miRNAs and previously studied targeted genes
MicroRNA Targeted gene Role of targeted gene
miR-155 STAT3, 
SOCS1
Cancer cell proliferation, antiapoptosis, 
epithelial-mesenchymal transion in breast13, 
pancreatic14, renal cell carcinoma15
BACH1 High N stage, poor clinical outcome in 
nasopharyngeal cancer16
miR-210 FGFRL1 Accelerates cancer cell proliferation by 
preventing cell cycle arrest in G1/G in 
poorly differentiated esophageal cancer17
Ephrin-A3 Suppress migration and survivial of 
endothelial cells18
miR-153, 
miR-200c
ZEB1, ZEB2, 
SNAI1
Repress E-cadherin expression and promote 
cancer cell migration and invasion19
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4. Protein expression level of target mRNA by immunohistochemistry
STAT3 and ZEB1 showed significant stepwise increase of expression 
in PIN and PCa compared to normal prostatic tissue (p<0.001). ZEB1 
expression was not found in normal prostatic tissue. Ephrin-A3 expression of 
PCa was significantly higher than PIN and normal prostatic tissue (p<0.001), 
whereas no signficant difference was found between PIN and normal prostatic 
tissue. FGFRL1 expression was significantly decreased in PIN (p=0.006) and 
PCa (p=0.002) than normal prostatic tissue , but showed no significant 
difference between PIN and PCa. BACH1 expression was significantly 
decreased in PIN than PCa (p=0.003) and normal prostatic tissue (p<0.001) (Fig. 
6). The result of protein expression scoring by immunohistochemistry and 
changes of expression level in PCa, PIN, and normal prostatic tissue are shown 
in Table 3 and Table 4. 
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Figure 6. Protein expression by immunohistochemistry applied to prostate 
cancer, prostatic intraepithelial neoplasia, and normal prostatic tissue. Prostate 
cancer (first column), prostatic intraepithelial neoplasia (second column), 
normal prostatic tissue (third column). STAT3 (A, B, C), ZEB1 (D, E, F), 
ephrin-A3 (G, H, I), FGFRL1 (J, K, L), BACH1 (M, N, O).  
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Table 3. Semiquantitatively measured protein expression level of target genes of 
cancer, prostatic intraepithelial neoplasia, and normal prostatic tissue by 
immunohistochemistry
Antibody PCa PIN Normal
STAT3 * 4.65±3.56 2.41±2.31 0.75±1.43
ZEB1 * 4.69±2.70 1.48±1.29 0
Ephrin-A3 * 2.51±2.97 1.02±1.70 0.84±1.74
FGFRL1 * 2.28±2.64 2.68±2.63 3.79±2.93
BACH1 * 1.26±1.45 0.58±1.21 1.32±2.15
PCa, prostate cancer; PIN, prostatic intraepithelial neoplasia; N, normal 
prostatic tissue
* p<0.05 by Friedman test 
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Table 4. Changes in protein expression level of target gene by 
immunohistochemistry
Protein PCa versus PIN PIN versus N PCa versus N
STAT3 I (<0.001) I (<0.001) I (<0.001)
ZEB1 I (<0.001) I (<0.001) I (0.031)
Ephrin-A3 I (0.001) NS I (<0.001)
FGFRL1 NS D (0.006) D (0.002)
BACH1 I (0.003) D (<0.001) NS
I indicates expression level that is increased in the first group versus other 
second group. D indicates decreased expression level in the first group versus 
other second group. P values in parentheses. NS, not significant; PCa, prostate 
cancer; PIN, prostatic intraepithelial neoplasia; N, normal prostatic tissue
IV. DISCUSSION
Since patients at early stage of PCa have near 100% of 5-year-survival 
rate compared to the patients at advanced stage, who have only 28% of 
5-year-survivial rate,20 early detection of cancer is deeply required for the 
improvement of survival rate in PCa. Prostate intraepithelial neoplasia (PIN), 
referred to the precursor lesion for the prostate carcinoma, is now accepted as 
early preinvasive neoplasm, which is only microscopically detectable.21 The 
rationale of PIN to be a precancerous lesion include some overlapping signs 
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in common; PIN demonstrates over 50% rate of coexistence with cancer,22
predominantly localizes in peripheral zone, and shows the increased 
incidence with age.23 In previous study, patients with high grade PIN showed 
significant association with multifocality of tumor, perineural invasion and 
biochemical recurrence, whereas patients lacking high grade PIN showed 
better disease free survival.24 However, it has been reported that patient with 
PIN had lower tumor volume,25 and organ-confined low stage in 84.4% of 
radical prostatectomy patients.26 In present study, we confirmed the better 
prognosis of patients with PIN compared to patients without PIN. Patients 
with PIN showed more favorable clinicopathologic parameters – lower PSA 
level, lower Gleason score, smaller tumor volume, less lymphovascular 
invasion and less lymph node metastasis. Given that PIN is an early lesion, 
preexisted PIN would be replaced by invasive PCa as disease progresses. It is 
also correlated with result of current study that patients with PIN showed 
more favorable clinicopathologic parameters and better overall survival 
compared to patients without PIN. However, we found no significant 
difference of pathologic T stage according to the presence of PIN, it would be 
due to the patient cohort of current study, because most patients had radical 
prostatectomy were pT2 or pT3. 
Recently, several molecular alterations in PCa and PIN have been 
reported.8 Chromosomal losses of 8p and gains of 8q are frequently found in 
both PIN and PCa. One of genetic alteration of PCa, TMPRSS2 gene fusion, is 
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observed in upto 17% of PIN.7 However, alteration of miRNAs between PIN 
and PCa is seldomly studied, 27 and many preexisting studies have been focused 
on progression and metastasis of PCa, rather than progression of PIN to PCa.9
Since miRNAs play multifunctional roles and regulate are multifunctional and 
regulate, specific miRNAs in carcinogenesis or PCa progression have not been 
established except miR-200 families, which is well known miRNAs involving 
EMT in many cancers.28,29
We found four miRNAs that were decreased in both PIN and PCa 
compared to benign prostatic tissue, which supports that PIN exists at one end 
of proceeding carcinogenesis of PCa. As multifunction miRNA, overexpression 
of miR-155 has been reported in breast, pancreas cancer and lymphoma,13,14,30
whereas downregulation of miR-155 has been found in melanoma and gastric 
cancer.31,32 Of two major target candidates of miR-155, STAT3 and BACH1 
showed significant differences in protein expression level among PCa, PIN, and 
normal prostatic tissue. However, although significant different level was found 
in BACH1, expression scores of PCa, PIN, and normal protstatic tissue were too 
low, all were under 2, which would have no practical implication, and should be 
validated in further study. In contrast, STAT3 showed obvious overexpression in 
PCa and PIN than normal prostatic tissue, increased gradually towards PCa. 
Stepwise overexpression of STAT3 suggests that PIN might be on the spectrum 
of carcinogenesis of PCa. Ni Z et al.33 showed that STAT3 activation was 
essential in progression of PCa, and correlated with its malignant potential, also 
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supports that STAT3 would be one of the important molecules altered in early 
carcinogenesis and progression of PCa. 
Mir-210 is one of the hypoxia-regulated miRs, acts as either oncogene 
or tumor suppressor.18 It is upregulated in the chronic hypoxic condition, which 
would be related to the tumor microenvironment.34 Ephrin-A3 is one of direct 
target of miR-210,18 and increased expression of its family has been reported in 
hepatocellular carcinoma.35 FGFRL1 is also regulated by miR-210, and 
downregulated of miR-210 and increased FGFRL1 have been observed in 
esophageal squamous cell carcinoma.17 In current study, FGFRL1 showed 
decreased expression in both PIN and PCa compared to normal prostatic tissue. 
However, together with BACH1, expression scores of FGFRL1 showed less 
than 2 fold although expression score itself showed significant difference. 
Although FGFRL1 has not been studied in PCa, intermediate molecule is 
presumed to be existed between miR-210 and FGFRL1. In addition, decreased 
FGFRL1 has been reported in urothelial carcinoma compared to the normal 
urothelium,36 tumor suppressive role of FGFRL1 needs to be further inestigated 
in PCa. We found that ephrin-A3 was significantly overexpressed in PCa 
compared to PIN and normal prostatic tissue, corresponded with previous study 
which suggested that miR-210 directly regulated ephrin-A3.18 We had 
discordant result of decreased level of miR-210 in present study compared with 
previous study in PCa which showed increased level of miR-210.34 However, 
this discrepancy might be from the different type of materials used in two 
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studies. We used 10 patients’ radical prostatectomy specimen, including paired 
PIN and PCa from each patient which were paraffine-embedded tissue. In 
contrast, previous study used 3 PCa cell lines, which was handled in fresh state, 
not in paraffin embedded state. Since miR-210 in PCa is yet intensely studied, 
further large-cohort study is needed to clarify the role of miR-210 in PCa and its 
pathogenesis. 
Mir-153 has been identified tumor suppressor. As downregulation of 
miR-153 is observed in cells of mesenchymal phenotype, miR-153 would be 
related with epithelial-mesenchymal transition (EMT).19 MiR-153 inhibits 
TGF-β-induced (EMT), and downregulated SNAI1 and ZEB2, acts as tumor 
surressor in oral cancer,19 breast cancer,37 and glioblastoma.38 Along with these 
studies, we also observed that miR-153 is down-regulated in both PIN and PCa, 
which suggests that EMT signal begins at the PIN state, early step of PCa 
carcinogenesis. Nonetheless, another study of PCa showed that miR-153 was 
upregulated in PCa, and thought to be potentially oncogenic since miR-153 
promoted proliferation of PCa through regulation of cell cycle and AKT 
signaling pathway, and directly targeted PTEN in PCa.39 As miR-153 has been 
rarely studied in PCa, further precise study with expanded cohort is required in 
PCa. 
MiR-200c is a member of miR-200 family, that well-known for their 
regulating EMT in cancer cells,29 together with miR-153.19 MiR-200c targets 
ZEB1 and ZEB2, which are repressors of e-cadherin, reduce cell motility in 
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cancer cells.29 Downregulation of miR-200c is found in various types of cancers, 
along with reduced e-cadherin expression, and correlates with metastasis and 
poor prognosis. Puhr M et al.28 investigated miR-200c in PCa, demonstrated 
that downregulation of miR-200c was related not only with low e-cadherin level 
and EMT but also with chemotherapy resistance. In the present study, 
significant downregulation of miR-200 was found in both PIN and PCa. This 
result implies that PIN would be already affected by EMT signals through 
miR-200c, which is also supported by significant expression of ZEB1 in PIN 
and PCa. Attenuation of basal cells in typical finding of PIN would be also 
explained by miR-200c downregulation reflecting the initiation of EMT process 
and invasiveness. 
Present study had several limitations. First, quantification of target 
mRNA was unable to assess due to the limited amount of microdissected PIN. 
Instead, we validated the protein expression level target genes of selected
miRNAs with immunohistochemical staining on whole section, which helps to 
semiquantitative assess of protein expression level and contrast the expression 
level clearly among PCa, PIN, and normal prostatic tissue. Second, functional 
study of interaction between selected miRNAs and targeted mRNAs has not 
been performed. Since miRNAs have multifunctional role and the degree of 
interactions with targeted mRNAs would show a great variety, validated result 
would have assisted the role of miRNAs in carcinogenesis in PCa. 
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V. CONCLUSION
In conclusion, we investigatved clinicopathological implication of PIN 
in PCa patients, and further compared the expression rate of miRNAs among 
the PIN, PCa, and normal prostatic tissue. Presence of PIN was associated with 
more favorable clinicopathological parameters and longer overall survival. 
Regarding miRNAs and protein expression, PIN and PCa showed significantly 
decreased miR-155, miR-210, miR-153, and miR-200c. Ephrin-A3 was 
significantly increased only in PCa than PIN and normal prostatic tissue, 
implied it contributed to the malignant characteristics in PCa. Interstingly, 
STAT3 and ZEB1 showed stepwise overexpression in PIN and PCa. This result 
suggests that STAT3 and ZEB1 could be the key molecule altered from early 
step of carcinogenesis in PCa and PIN would be already in process of 
carcinogenesis as precursor of PCa.
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ABSTRACT
Prostate intraepithelial neoplasia 와 prostate cancer 에서의 microRNA 
발현의 차이와 carcinogenesis 에 관여하는 연관된 전사 인자
<지도교수 조 남 훈>
연세대학교 대학원 의학과
차 윤 진
목적: Prostatic intraepithelial neoplasia (PIN) 는 prostate cancer (PCa) 
의 전구병변으로 여겨지는데, 조직학적으로 세포학적 이형성과
기저세포의 유지를 특징으로 하며 분자생물학적 기전은 잘
밝혀져 있지 않다. 본 연구에서는 PIN 과 PCa 발생에 관여하는
microRNAs (miRNAs) 와 targeted mRNAs 를 규명하고
임상병리학적 의의를 찾고자 하였다. 
연구방법: 388명의 radical prostatectomy 환자 중 69.3% 의
환자에서 PIN 이 관찰되었으며, large PIN 은 56명의 환자에서
관찰되었다. PIN 의 유무에 따라 임상병리학적 인자에 대한
분석을 시행하였다. miRNAs 와 mRNA 의 분석을 위해 large PIN 
은 macrodissection, small PIN 은 laser capture microdissection 을
통해 formalin-fixed paraffin embedded tissue 에서 조직을
채취하였다. miRNA microarray 분석에서 각 환자의 PIN 과 PCa 
에서 정상 prostate 조직에 비해 발현이 떨어진 miRNAs 를
선정하고, FGFR1, BACH1, ephrin-A3, STAT3, ZEB1 에 대한
면역조직화학 염색을 통해 PCa, PIN, 정상 prostate 조직에서의
단백질 발현을 분석하였다. 
결과: PIN 이 있는 환자들은 PIN 이 없는 환자들에 비해
lymphovascular invasion, lymph node metastasis, tumor volume, 
Gleason score 가 유의하게 낮았으며, 낮은 사망률과 높은
생존기간을 보였다. 4개의 miRNA- mir-155, mir-210, mir-153, and 
- 35 -
mir-200c- 가 PCa 와 PIN 에서 낮은 발현을 보였고, 
면역조직화학염색을 통한 단백질 발현을 보았을 때, PCa 에서
PIN 과 정상 prostate 조직에 비해 STAT3, ZEB1, ephrin-A3 의
발현이 높이 나타났으며, STAT3 와 ZEB1 은 정상 prostate 
조직에서 PCa 로 가면서 단계적으로 발현이 높아졌다.
결론: PIN 이 있는 환자에서 더 좋은 임상병리학적 지표와 긴
생존기간은 PCa 가 PIN 에서 좀더 진행된 병변임을 나타낸다. 
또한 PIN 과 PCa 에서 cancer-related miRNAs 의 낮은 발현이
관찰되고, STAT3 와 ZEB1 의 단계적 발현의 증가는 PIN 이
PCa 의 전구병변이며, 초기의 carcinogenesis 에 분자생물학적
기전이 관여한다는 가설을 뒷받침한다. 
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